Literature DB >> 2456008

Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers.

H J Helin1, M J Helle, M L Helin, J J Isola.   

Abstract

Monoclonal antibodies to human estrogen receptor (ER), and rabbit progesterone receptor (PR), also recognizing human PR, were used to detect the receptors by peroxidase immunocytochemistry in frozen sections of 124 primary breast carcinomas. Both ER and PR were almost exclusively located in carcinoma cell nuclei, with heterogeneous distribution and intensity. The staining results were evaluated semiquantitatively (histoscore), based on the percentage of positively stained carcinoma cells and nuclear staining intensity. The receptor status thus determined was as follows: ER+PR+ in 50 patients, ER+PR- in 23, ER-PR- in 26, and ER-PR+ in 3 patients. There was a 79% (ER) or 70% (PR) agreement in the positivity/negativity between the immunocytochemical and steroid-binding assay (in 102 patients) with a highly significant correlation. The histoscore values increased significantly with cytosol receptor levels (ER, r = 0.623, P less than 0.001; PR, r = 0.366, P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2456008     DOI: 10.1093/ajcp/90.2.137

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Imprint cytology in immunocytochemical analysis of oestrogen and progesterone receptors of breast carcinoma.

Authors:  H J Helin; J J Isola; M J Helin; M J Helle; K J Krohn
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

2.  Demonstration of progesterone receptors in paraffin wax sections of breast carcinoma.

Authors:  S Soomro; S Shousha
Journal:  J Clin Pathol       Date:  1990-08       Impact factor: 3.411

3.  Immunohistochemical assessment of estrogen and progesterone receptors in stored imprints and cryostat sections of breast carcinomas.

Authors:  C M DeRosa; L Ozzello; D V Habif; J G Konrath; G L Greene
Journal:  Ann Surg       Date:  1989-08       Impact factor: 12.969

4.  Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters.

Authors:  M Helle; M Helin; J Isola; H Helin
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

5.  Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients.

Authors:  H J Helin; J J Isola; M J Helle; H Adlercreutz
Journal:  Breast Cancer Res Treat       Date:  1988-09       Impact factor: 4.872

6.  Distribution of estrogen and progesteron receptors in the uterus: an immunohistochemical study in the immature and adult pseudopregnant rabbit.

Authors:  C Hegele-Hartung; K Chwalisz; H M Beier
Journal:  Histochemistry       Date:  1992

7.  Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer.

Authors:  G Gasparini; F Pozza; R Dittadi; S Meli; S Cazzavillan; P Bevilacqua
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Estrogen receptors in 699 primary breast cancers: a comparison of immunohistochemical and biochemical methods.

Authors:  A Molino; R Micciolo; M Turazza; F Bonetti; Q Piubello; A Corgnati; L Sperotto; G Martignoni; A Bonetti; R Nortilli
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

9.  Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma.

Authors:  H Helin; J Isola; M Helle; T Koivula
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

10.  Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo.

Authors:  W C Duivenvoorden; L K Beatty; S Lhotak; B Hill; I Mak; G Paulin; D Gallino; S Popovic; R C Austin; J H Pinthus
Journal:  Br J Cancer       Date:  2013-01-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.